Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
RCAN1-4 is a thyroid cancer growth and metastasis suppressor
Chaojie Wang, … , Neal Pohlman, Matthew D. Ringel
Chaojie Wang, … , Neal Pohlman, Matthew D. Ringel
Published March 9, 2017
Citation Information: JCI Insight. 2017;2(5):e90651. https://doi.org/10.1172/jci.insight.90651.
View: Text | PDF
Research Article Endocrinology Oncology

RCAN1-4 is a thyroid cancer growth and metastasis suppressor

  • Text
  • PDF
Abstract

Metastasis suppressors are key regulators of tumor growth, invasion, and metastases. Loss of metastasis suppressors has been associated with aggressive tumor behaviors and metastatic progression. We previously showed that regulator of calcineurin 1, isoform 4 (RCAN1-4) was upregulated by the KiSS1 metastatic suppression pathway and could inhibit cell motility when overexpressed in cancer cells. To test the effects of endogenous RCAN1-4 loss on thyroid cancer in vivo, we developed RCAN1-4 knockdown stable cells. Subcutaneous xenograft models demonstrated that RCAN1-4 knockdown promotes tumor growth. Intravenous metastasis models demonstrated that RCAN1-4 loss promotes tumor metastases to the lungs and their subsequent growth. Finally, stable induction of RCAN1-4 expression reduced thyroid cancer cell growth and invasion. Microarray analysis predicted that nuclear factor, erythroid 2-like 3 (NFE2L3) was a pivotal downstream effector of RCAN1-4. NFE2L3 overexpression was shown to be necessary for RCAN1-4–mediated enhanced growth and invasiveness and NEF2L3 overexpression independently increased cell invasion. In human samples, NFE2L3 was overexpressed in TCGA thyroid cancer samples versus normal tissues and NFE2L3 overexpression was demonstrated in distant metastasis samples from thyroid cancer patients. In conclusion, we provide the first evidence to our knowledge that RCAN1-4 is a growth and metastasis suppressor in vivo and that it functions in part through NFE2L3.

Authors

Chaojie Wang, Motoyasu Saji, Steven E. Justiniano, Adlina Mohd Yusof, Xiaoli Zhang, Lianbo Yu, Soledad Fernández, Paul Wakely Jr., Krista La Perle, Hiroshi Nakanishi, Neal Pohlman, Matthew D. Ringel

×

Figure 1

RCAN1-4 knockdown promotes cell 3D spheroid growth in vitro.

Options: View larger image (or click on image) Download as PowerPoint
RCAN1-4 knockdown promotes cell 3D spheroid growth in vitro.
(A) Endogen...
(A) Endogenous RCAN1-4 expression was analyzed by Western blot in 6 established thyroid cancer cell lines stably expressing luciferase. (B) RCAN1-4 knockdown efficiency of shRCAN1-4 stable cells was confirmed using Western blot. (C) Cells were seeded in 6-well plates in triplicate, and viable cells were counted at 24, 48, and 72 hours after seeding. Each data point represents the mean ± standard error of 3 independent experiments. (D) Cells were seeded on Corning spheroid 96-well microplates and incubated for 2 or 3 days for FTC236 and HTh74 cells, respectively. Cell viability was determined; the data were normalized to the corresponding shCtrl cells. Error bars represent SEM. A linear mixed model was used to determine the statistical significance. ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts